The XYZ: W. Taylor Cottle, Cofounder and CEO of Aptabridge Therapeutics, Inc and Nucleate Baltimore/DC Chapter You may have seen him around the Johns Hopkins campus as a student leader [….]
This exceptional in-person Spatial Biology event consists of a two-day symposium and a one-day hands-on in silico based laboratory workshop. The symposium features esteemed experts from pathology, spatial biology, multiplex [….]
Rise Therapeutics Announces FDA Clearance of its IND Application to Initiate a Phase 1 Study of an Oral Immunotherapy for the Treatment of Ulcerative Colitis 31 January 2023
Rockville, Maryland, January 31st, 2023 – Rise Therapeutics, a biopharmaceutical company engaged in developing novel oral synthetic biology medicines, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a Phase 1 clinical trial of its lead program candidate, R-3750.
R-3750 is a synthetic biology-based cellular immunotherapy being developed for the treatment of Inflammatory Bowel Disease (IBD). Optimized for intestinal delivery of a key microbiome-associated immune regulatory molecule whose natural role is to control host immune function, R-3750 is an oral therapy that has the potential to treat the underlying immunological basis of gastrointestinal-associated inflammatory disease. R-3750 leverages Rise Therapeutics’ proprietary drug delivery platform to orally deliver targeted biological therapy that engages a specific receptor expressed on dendritic cells, reducing inflammation and inducing colonic immune homeostasis. As a result, R-3750 improves gut membrane barrier integrity reestablishing a normal microbiome composition.
The Phase 1 trial will be a single and repeat dose study assessing the safety and tolerability, drug exposure, and clinical…
This four day program is ideal for those who are looking for an in-depth, hands-on introduction to Flow Cytometry. The instructors will focus on a broad spectrum of flow cytometric [….]
This four day program is divided into a two-day symposium with lectures presented by world class scientists in the field of immuno-oncology and with representation by all the main multiplex [….]
Immunomic Therapeutics Receives FDA Fast Track Designation for ITI-3000, a pDNA Vaccine, in Development for the Treatment of Merkel Cell Carcinoma November 08, 2022 08:30 AM Eastern Standard Time ROCKVILLE, [….]
Context Therapeutics Inc., a women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers, and Tyligand Bioscience, Ltd., a leader in small molecule drug discovery and development, today announced the successful completion of ONA-XR (onapristone extended release) manufacturing process optimization pursuant to the collaboration agreement entered into between the parties in March 2020.
WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs®) for cancer immunotherapy, today announced the appointment of Co-Founder Kimberly Noonan, PhD, MPH, to Executive Vice President, Chief Science & Technology Officer. In this role, Dr. Noonan’s leadership will expand to include WindMIL’s efforts in manufacturing and manufacturing science and technology (MS&T).
Over the recent decades, cancer immunotherapy research has made significant advances. In our continued quest to cure cancer, a commercial incentive is necessary to counterbalance the costs and risks associated with the research and development of cancer immunotherapies and to encourage new inventions.
Under the joint research collaboration agreement, which covers activities from candidate drug generation up until IND-enabling studies, each company will be responsible for its own costs. The parties may continue further development of the resulting bispecific molecule under a separate co-development collaboration and licensing agreement.
